- $398.62m
- $290.26m
- $4.53m
- 50
- 10
- 62
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.23 | ||
| Price to Tang. Book | 2.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 87.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.36% | ||
| Return on Equity | -58.04% | ||
| Operating Margin | -2421.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.78 | 4.78 | 5.75 | 5.72 | 4.53 | 11.49 | 22.2 | 17.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.
Directors
- Ivana Liebisch NEC (53)
- Sean McClain CEO (31)
- Gregory Schiffman CFO (63)
- Andreas Pihl COO (60)
- Matthew Weinstock CTO (35)
- Sarah Korman GCN (42)
- Nikhil Goel OTH (41)
- Joseph Sirosh DRC
- Eli Casdin IND (48)
- Zachariah Jonasson IND (49)
- Karen McGinnis IND (54)
- Amrit Nagpal IND (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 5th, 2020
- Public Since
- July 22nd, 2021
- No. of Shareholders
- 46
- No. of Employees
- 156
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 127,353,236
- Address
- 18105 Se Mill Plain Blvd, VANCOUVER, 98683
- Web
- https://www.absci.com/
- Phone
- +1 3609491041
- Auditors
- Ernst & Young LLP
Upcoming Events for ABSI
Q1 2025 Absci Corp Earnings Call
Absci Corp Annual Shareholders Meeting
Q2 2025 Absci Corp Earnings Release
Similar to ABSI
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the AbSci share price?
As of Today at 19:02 UTC, shares in AbSci are trading at $3.13. This share price information is delayed by 15 minutes.
How has the AbSci share price performed this year?
Shares in AbSci last closed at $3.13 and the price had moved by -29.74% over the past 365 days. In terms of relative price strength the AbSci share price has underperformed the S&P500 Index by -35.15% over the past year.
What are the analyst and broker recommendations for AbSci?
The overall consensus recommendation for AbSci is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AbSci dividend yield?
AbSci does not currently pay a dividend.
Does AbSci pay a dividend?
AbSci does not currently pay a dividend.
When does AbSci next pay dividends?
AbSci does not currently pay a dividend.
How do I buy AbSci shares?
To buy shares in AbSci you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AbSci?
As of the previous close price of $3.13, shares in AbSci had a market capitalisation of $398.62m.
Where are AbSci shares listed?
Here are the trading details for AbSci:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABSI
What kind of share is AbSci?
Based on an overall assessment of its quality, value and momentum AbSci is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AbSci share price forecast for 2025?
The analyst consensus target price for shares in AbSci is $9.13. That is 191.69% above the last closing price of $3.13.
Analysts covering AbSci currently have a consensus Earnings Per Share (EPS) forecast of -$0.89 for the next financial year.
Find out moreWhat is the trend in the AbSci share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AbSci. Over the past six months, its share price has underperformed the S&P500 Index by -18.94%.
As of the last closing price of $3.13, shares in AbSci were trading -14.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AbSci PE Ratio?
The AbSci PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AbSci?
AbSci's management team is headed by:
- Ivana Liebisch - NEC
- Sean McClain - CEO
- Gregory Schiffman - CFO
- Andreas Pihl - COO
- Matthew Weinstock - CTO
- Sarah Korman - GCN
- Nikhil Goel - OTH
- Joseph Sirosh - DRC
- Eli Casdin - IND
- Zachariah Jonasson - IND
- Karen McGinnis - IND
- Amrit Nagpal - IND